Neurocrine Biosciences, Inc. (NASDAQ:NBIX) reached 17.74% versus a 1-year low price of $37.35. The stock was last seen 3.48% higher, reaching at $43.97 on Jun. 16, 2017. At recent session, the prices were hovering between $41.92 and $44.15. This company shares are 60.95% off its target price of $70.77 and the current market capitalization stands at $3.84B. The recent change has given its price a -10.65% deficit over SMA 50 and -20.6% deficit over its 52-week high. The stock witnessed -16.76% declines, -1.19% declines and 1.71% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found NBIX’s volatility during a week at 4.02% and during a month it has been found around 4.13%.Neurocrine Biosciences, Inc. (NBIX) Top Holders
Institutional investors currently hold around $3.75 billion or 99.8% in NBIX stock. Look at its top three institutional owners. Fmr Llc owns $528.97 million in Neurocrine Biosciences, Inc., which represents roughly 13.78% of the company’s market cap and approximately 14.11% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 6,735,965 shares of the stock are valued at $296.18 million. The third largest holder is Blackrock Inc., which currently holds $221.25 million worth of this stock and that ownership represents nearly 5.76% of its market capitalization.Neurocrine Biosciences, Inc. 13F Filings
At the end of Mar reporting period, 111 institutional holders increased their position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by some 13,222,702 shares, 118 decreased positions by 14,023,009 and 29 held positions by 58,047,024. That puts total institutional holdings at 85,292,735 shares, according to SEC filings. The stock grabbed 35 new institutional investments totaling 2,729,676 shares while 37 institutional investors sold out their entire positions totaling 3,092,998 shares.Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Trades
Multiple company employees have indulged in significant insider trading. Neurocrine Biosciences, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Research Officer Grigoriadis Dimitri E. has sold 10,000 shares of Neurocrine Biosciences, Inc. (NBIX) in trading session dated May. 23, 2017. These shares are worth $533,900 and were traded at $53.39 each. The SEC filing shows that Lloyd-Smith Malcolm performed a sale of 9,960 shares. The Chief Regulatory Officer disposed these shares by way of transaction on May. 19, 2017. The company’s shares were given away at $53.63 per share worth to an income of some $534,155 on account of Lloyd-Smith Malcolm.
Chief Legal Officer, Lippoldt Darin, sold 10,000 common shares of Neurocrine Biosciences, Inc. (NBIX) in the open market. In a transaction dated May. 18, 2017, the shares were put up for sale at an average price of $53.27, raking in a sum of $532,700. After this sale, 13,157 common shares of NBIX are directly owned by the insider, with total stake valued at $578,513.
In the transaction dated May. 18, 2017, the great number of shares disposed came courtesy the Chief Medical Officer; OBrien Christopher Flint disposed a total of 105,634 shares at an average price of $53.32, amounting to approximately $5,632,405. The insider now directly owns 48,973 shares worth $2,153,343.Neurocrine Biosciences, Inc. (NBIX) Analyst Guide
Several analysts have released their opinion on Neurocrine Biosciences, Inc. (NASDAQ:NBIX), with 10 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.09 average brokerage recommendation.